- Impressive Breakthrough: Eli Lilly's new weight-loss drug, orforglipron, showcases remarkable trial results, outperforming competitors like Ozempic.
- Analyst Optimism: Analysts anticipate significant growth, with average price targets suggesting substantial upside potential.
- Value Insights: GuruFocus estimates reveal a promising GF Value, indicating a considerable future valuation boost.
Eli Lilly (NYSE: LLY) is making headlines with a robust 14% stock increase, thanks to successful trials of its innovative weight-loss medication, orforglipron. This groundbreaking drug, expected to strategically expand the lucrative $130 billion market, has demonstrated superior weight-loss outcomes compared to Ozempic in preliminary studies. Eli Lilly is gearing up for a comprehensive regulatory submission by the end of the year, signaling potential market dominance.
Wall Street Analysts Forecast
According to projections from 25 market analysts, Eli Lilly and Co (LLY, Financial) holds an average one-year price target of $1,012.05. The forecasts range from a high of $1,190.00 to a low of $800.00, offering an anticipated upside of 20.49% from its current share price of $839.96. For an in-depth analysis, visit the Eli Lilly and Co (LLY) Forecast page.
The collective sentiment from 29 brokerage firms rates Eli Lilly and Co's (LLY, Financial) average brokerage recommendation at 1.9, categorizing it as "Outperform." This rating is part of a scale where 1 indicates a Strong Buy and 5 a Sell.
GuruFocus provides a compelling estimate for Eli Lilly's (LLY, Financial) GF Value at $1,126.38 for the upcoming year. This projection suggests an impressive upside potential of 34.1% from its current trading value of $839.96. The GF Value is a calculated estimate of the stock’s fair trading value, derived from historical trading multiples, past business growth, and future business performance projections. For further insights, explore the Eli Lilly and Co (LLY) Summary page.
